Iovance Biotherapeutics Inc (IOVA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) have received an average recommendation of “Buy” from the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $21.07.

IOVA has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. HC Wainwright set a $16.00 target price on shares of Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday, January 17th. Wells Fargo restated a “buy” rating and set a $23.00 target price on shares of Iovance Biotherapeutics in a report on Monday, January 29th. Finally, B. Riley restated a “buy” rating and set a $18.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, January 25th.

How to Become a New Pot Stock Millionaire

A number of hedge funds and other institutional investors have recently bought and sold shares of IOVA. Bank of New York Mellon Corp raised its position in Iovance Biotherapeutics by 7.1% during the third quarter. Bank of New York Mellon Corp now owns 261,692 shares of the biotechnology company’s stock worth $2,028,000 after acquiring an additional 17,338 shares in the last quarter. SG Americas Securities LLC raised its position in Iovance Biotherapeutics by 385.3% during the third quarter. SG Americas Securities LLC now owns 50,295 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 39,931 shares in the last quarter. JPMorgan Chase & Co. raised its position in Iovance Biotherapeutics by 63.4% during the third quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock worth $14,059,000 after acquiring an additional 690,527 shares in the last quarter. Wells Fargo & Company MN raised its position in Iovance Biotherapeutics by 44.2% during the third quarter. Wells Fargo & Company MN now owns 103,528 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 31,724 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Iovance Biotherapeutics by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 222,015 shares of the biotechnology company’s stock worth $1,721,000 after acquiring an additional 12,883 shares in the last quarter. 64.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Iovance Biotherapeutics stock traded up $0.70 on Thursday, hitting $15.45. The company had a trading volume of 563,509 shares, compared to its average volume of 1,091,406. The stock has a market capitalization of $1,364.05, a PE ratio of -10.96 and a beta of 5.74. Iovance Biotherapeutics has a twelve month low of $4.45 and a twelve month high of $19.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.04). equities research analysts forecast that Iovance Biotherapeutics will post -1.25 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Iovance Biotherapeutics Inc (IOVA) Given Consensus Recommendation of “Buy” by Brokerages” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://sportsperspectives.com/2018/04/17/iovance-biotherapeutics-inc-iova-given-consensus-recommendation-of-buy-by-brokerages.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply